Clinical and Experimental Medicine最新文献_第3页

Navigating the complexities: challenges and opportunities in conversion therapy for advanced hepatocellular carcinoma. 驾驭复杂性：晚期肝细胞癌转化治疗的挑战与机遇。

IF 3.2 4区医学

Clinical and Experimental Medicine Pub Date : 2025-05-18 DOI: 10.1007/s10238-025-01698-9

Yubo Jiang, Xiaofeng Dong, Yingying Zhang, Feiyan Su, Lei Zhao, Xuetao Shi, Jingtao Zhong

{"title":"Navigating the complexities: challenges and opportunities in conversion therapy for advanced hepatocellular carcinoma.","authors":"Yubo Jiang, Xiaofeng Dong, Yingying Zhang, Feiyan Su, Lei Zhao, Xuetao Shi, Jingtao Zhong","doi":"10.1007/s10238-025-01698-9","DOIUrl":"10.1007/s10238-025-01698-9","url":null,"abstract":"Primary liver cancer ranks as the sixth most prevalent malignant tumor and stands as the second leading cause of cancer-related mortality globally, posing a significant threat to public health. Hepatocellular carcinoma (HCC) is the most common type of liver cancer worldwide. Surgical resection remains the cornerstone treatment for achieving radical cure and prolonged survival in HCC patients. Contrary to Western countries, the majority of HCC patients in China present with hepatitis B virus infection and consequent liver cirrhosis, with most cases diagnosed at an intermediate or advanced stage. This complexity results in a poor prognosis. Recent advancements in local therapeutic techniques and the introduction of systemic therapies, including targeted and immunotherapy agents, have provided new avenues for both clinical and basic conversion therapy for advanced HCC. Integrating multi-dimensional local and systemic therapies, multi-modal sequential, and comprehensive multidisciplinary approaches into the management of HCC patients has demonstrated promising conversion success rates. This holistic management strategy involves combining multiple treatment modalities vertically and coordinating various disciplines horizontally. However, significant challenges remain, including the precise selection of patients eligible for conversion therapy, the optimal choice of conversion therapy regimens, and the accurate determination of surgical timing post-conversion therapy. Addressing these challenges is crucial for hepatobiliary surgeons. High-quality, randomized controlled trials are urgently needed to generate robust evidence for clinical practice. This review aims to synthesize the latest research developments both in China and internationally and examines key issues in the realm of HCC conversion therapy.","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"169"},"PeriodicalIF":3.2,"publicationDate":"2025-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12086121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Machine learning and single-cell analysis uncover distinctive characteristics of CD300LG within the TNBC immune microenvironment: experimental validation. 机器学习和单细胞分析揭示了TNBC免疫微环境中CD300LG的独特特征：实验验证。

IF 3.2 4区医学

Clinical and Experimental Medicine Pub Date : 2025-05-17 DOI: 10.1007/s10238-025-01690-3

Baoxi Zhu, Hong Wan, Zichen Ling, Han Jiang, Jing Pei

{"title":"Machine learning and single-cell analysis uncover distinctive characteristics of CD300LG within the TNBC immune microenvironment: experimental validation.","authors":"Baoxi Zhu, Hong Wan, Zichen Ling, Han Jiang, Jing Pei","doi":"10.1007/s10238-025-01690-3","DOIUrl":"10.1007/s10238-025-01690-3","url":null,"abstract":"Investigating the essential function of CD300LG within the tumor microenvironment in triple-negative breast cancer (TNBC). Transcriptomic and single-cell data from TNBC were systematically collected and integrated. Four machine learning algorithms were employed to identify distinct target genes in TNBC patients. Specifically, CIBERSORT and ssGSEA algorithms were utilized to elucidate immune infiltration patterns, whereas TIDE and TCGA algorithms predicted immune-related outcomes. Moreover, single-cell sequencing data were analyzed to investigate the function of CD300LG-positive cells within the tumor microenvironment. Finally, immunofluorescence staining confirmed the significance of CD300LG in tumor phenotyping. After machine learning screening and independent dataset validation, CD300LG was identified as a unique prognostic biomarker for triple-negative breast cancer. Enrichment analysis revealed that CD300LG expression is strongly linked to immune infiltration and inflammation-related pathways, especially those associated with the cell cycle. The presence of CD8+ T cells and M1-type macrophages was elevated in the CD300LG higher group, whereas the abundance of M2-type macrophage infiltration showed a significant decrease. Immunotherapy prediction models indicated that individuals with low CD300LG expression exhibited better responses to PD-1 therapy. Additionally, single-cell RNA sequencing and immunofluorescence analyses uncovered a robust association between CD300LG and genes involved in tumor invasion. CD300LG plays a pivotal role in the tumor microenvironment of TNBC and represents a promising therapeutic target.","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"167"},"PeriodicalIF":3.2,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12085369/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144092998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nanotechnology in leukemia therapy: revolutionizing targeted drug delivery and immune modulation. 纳米技术在白血病治疗：革命性的靶向药物输送和免疫调节。

IF 3.2 4区医学

Clinical and Experimental Medicine Pub Date : 2025-05-17 DOI: 10.1007/s10238-025-01686-z

Ashok Kumar Bishoyi, Sina Nouri, Ahmed Hussen, Alireza Bayani, Mohammad Navid Khaksari, Hamed Soleimani Samarkhazan

{"title":"Nanotechnology in leukemia therapy: revolutionizing targeted drug delivery and immune modulation.","authors":"Ashok Kumar Bishoyi, Sina Nouri, Ahmed Hussen, Alireza Bayani, Mohammad Navid Khaksari, Hamed Soleimani Samarkhazan","doi":"10.1007/s10238-025-01686-z","DOIUrl":"10.1007/s10238-025-01686-z","url":null,"abstract":"Leukemia, a group of blood cancers, presents a significant global health challenge. Despite advancements in conventional therapies like chemotherapy and immunotherapy, the need for more effective and less toxic treatments remains. Nanotechnology offers a promising avenue for targeted drug delivery and immune modulation in the fight against leukemia. Through the utilization of nanomaterials' special qualities, like their small size, large surface area, and capacity to transport a variety of payloads, scientists are creating novel ways to get around the drawbacks of conventional treatments. These strategies include targeted drug delivery, immune cell activation, and overcoming drug resistance. However, challenges remain in translating these promising nanotechnological approaches into clinical applications. Addressing issues such as toxicity, biodistribution, and regulatory hurdles is crucial for the successful development of nanomedicine for leukemia. In conclusion, nanotechnology offers a promising future for the treatment of leukemia. Continued research and development are essential to unlock the full potential of nanomaterials and improve patient outcomes. The potential of nanotechnology-based strategies to improve the effectiveness of leukemia treatments is explored in this review. We go over the function of different nanomaterials in delivering therapeutic agents to leukemia cells, such as liposomes, polymeric nanoparticles, and inorganic anoparticles. We also investigate the engineering of nanomaterials to influence the immune system and promote anti-tumor reactions.","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"166"},"PeriodicalIF":3.2,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12084282/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144085977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Complex association of mean corpuscular volume and outcomes in patients with aplastic anemia treated with cyclosporine A plus androgen or cyclosporine A alone. 环孢素A加雄激素或单环孢素A治疗再生障碍性贫血患者平均红细胞体积与预后的复杂关系

IF 3.2 4区医学

Clinical and Experimental Medicine Pub Date : 2025-05-16 DOI: 10.1007/s10238-025-01652-9

Li Han, XueDong Shi, ShuQi Wang, QiuShuang Wang, AnQi Xia, Jiang Cao, KaiLin Xu, Hai Cheng

{"title":"Complex association of mean corpuscular volume and outcomes in patients with aplastic anemia treated with cyclosporine A plus androgen or cyclosporine A alone.","authors":"Li Han, XueDong Shi, ShuQi Wang, QiuShuang Wang, AnQi Xia, Jiang Cao, KaiLin Xu, Hai Cheng","doi":"10.1007/s10238-025-01652-9","DOIUrl":"10.1007/s10238-025-01652-9","url":null,"abstract":"The aim of this study was to explore the prognostic value of mean corpuscular volume (MCV) in newly diagnosed aplastic anemia (AA) patients treated with cyclosporine A (CsA) plus androgen or CsA alone. The clinical data of 181 newly diagnosed patients with aplastic anemia from April 2008 to September 2020 in the Affiliated Hospital of Xuzhou Medical University were retrospectively analyzed. According to the MCV levels, the patients were divided into a high-MCV group (107/181) and a normal-MCV group (74/181). We investigated the effect of MCV outcomes in patients with AA. Between the high-MCV and normal-MCV groups, neutrophil count, red blood cell count, platelet count, reticulocyte count, disease severity, lymphocytes, and granulocytes were significantly different (P < 0.05). The overall response rates (CR + PR) were 69.16% and 59.46% in the high-MCV and normal-MCV groups, respectively. The duration of response was not significantly different between MCV groups. The high-MCV patients had an improved 5-year overall survival and progression-free survival compared to the normal-MCV patients (94.40% vs. 68.10%; 71.80% vs. 60.30%, P < 0.001). Regarding hemogram restoration, the leukocyte, neutrophil, hemoglobin, and platelet recovery was accelerated in the high-MCV group (P < 0.05). Furthermore, MCV levels were positively correlated with reticulocyte count, reticulocyte percentage, high-fluorescence reticulocyte, medium-fluorescence reticulocyte, and immature reticulocyte fraction; on the other hand, MCV levels were negatively correlated with low fluorescent reticulocyte. In conclusion, aplastic anemia patients with a high MCV were a better prognostic factor, and the patients with high MCV may have better residual bone marrow hematopoietic function than those with normal MCV.","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"165"},"PeriodicalIF":3.2,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12084278/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Myosteatosis and the survival of patients with hepatocellular carcinoma: a meta-analysis. 肌骨化病与肝细胞癌患者的生存：一项荟萃分析。

IF 3.2 4区医学

Clinical and Experimental Medicine Pub Date : 2025-05-16 DOI: 10.1007/s10238-025-01671-6

Yongjuan Wu, Guangyuan Cheng, Jun Han, Qingsong Yang

{"title":"Myosteatosis and the survival of patients with hepatocellular carcinoma: a meta-analysis.","authors":"Yongjuan Wu, Guangyuan Cheng, Jun Han, Qingsong Yang","doi":"10.1007/s10238-025-01671-6","DOIUrl":"10.1007/s10238-025-01671-6","url":null,"abstract":"Myosteatosis, characterized by fat infiltration into skeletal muscle, is increasingly recognized as a prognostic factor in hepatocellular carcinoma (HCC), although the results were not consistent. This meta-analysis aimed to summarize impact on overall survival (OS) and progression-free survival (PFS) in patients with HCC.A systematic search of PubMed, Embase, and Web of Science was conducted to identify observational studies reporting survival outcomes in HCC patients with and without myosteatosis. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using a random-effects model. A total of 24 retrospective cohort studies involving 7436 HCC patients were included. Myosteatosis was significantly associated with poorer OS (HR: 1.60, 95% CI: 1.40-1.83, p < 0.001, I2 = 65%) and PFS (HR: 1.53, 95% CI: 1.33-1.76, p < 0.001, I2 = 36%). Subgroup analysis revealed a stronger association in Asian studies (HR: 1.74 for OS; 1.57 for PFS) compared to European studies (HR: 1.08 for OS; 1.05 for PFS). The prognostic impact remained significant regardless of anticancer treatment type, myosteatosis assessment method, sex-specific or universal cutoff values, and follow-up duration (p for subgroup differences all > 0.05). The results remained significant in studies adjusting for sarcopenia (HR: 1.89 for OS; 1.50 for PFS). Meta-regression analyses did not suggest any of the following variables may affect the results, including sample size, mean ages of the patients, proportions of men, follow-up durations, and study quality scores (p all > 0.05).Myosteatosis is independently associated with worse survival in HCC patients, particularly in Asian populations. These findings highlight the significance of assessing muscle quality as a prognostic factor in HCC.","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"164"},"PeriodicalIF":3.2,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12084174/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bidirectional association between uveitis and psoriasis: a systematic review and meta-analysis. 葡萄膜炎与牛皮癣的双向关联：一项系统综述和荟萃分析。

IF 3.2 4区医学

Clinical and Experimental Medicine Pub Date : 2025-05-15 DOI: 10.1007/s10238-025-01693-0

Doudou Wu, Rui Cai, Ying Pang, Jie Ma, Bailin Chen, Siran Bao, Kaili Zheng, Wenbo Jiang, Yiming Qi, Nuo Li

{"title":"Bidirectional association between uveitis and psoriasis: a systematic review and meta-analysis.","authors":"Doudou Wu, Rui Cai, Ying Pang, Jie Ma, Bailin Chen, Siran Bao, Kaili Zheng, Wenbo Jiang, Yiming Qi, Nuo Li","doi":"10.1007/s10238-025-01693-0","DOIUrl":"10.1007/s10238-025-01693-0","url":null,"abstract":"Background: In recent years, the prevalence of uveitis among patients with psoriasis has shown a noticeable upward trend. Previous studies have investigated the immunological mechanisms underlying the potential connection between psoriasis and uveitis, but systematic studies exploring their bidirectional relationship is absent. This study aims to systematically evaluate the bidirectional association between psoriasis and uveitis to provide evidence.Methods: We thoroughly searched PubMed, Embase, and the Cochrane Library for relevant observational studies published from the inception of these databases up to Mar 11th, 2024. Our systematic review was based on priori protocol pre-registered in PROSPERO (No. CRD42024522464). Risk and bias assessments were analyzed using STATA 16.0.Results: We analyzed the results from 7 studies involving 81,775,820 subjects. The results showed that the incidence of uveitis was higher in patients with psoriasis compared to patients without psoriasis (OR = 1.16, 95% CI: 1.11-1.21). At the same time, patients with uveitis showed heightened susceptibility to psoriasis (OR = 1.52, 95% CI: 1.34-1.70, I2: 90.6%, P < 0.01). The subgroup analysis found that uveitis affects the severity and type of psoriasis.Conclusions: The current systematic review and meta-analysis found a bidirectional association between psoriasis and uveitis. Notably, patients with severe psoriasis and psoriasis with joint symptoms should be informed about their increased risk to developing uveitis.","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"161"},"PeriodicalIF":3.2,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12081564/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identification and functional characterization of hub genes CLTA, EDIL3, HAPLN1, and HIP1 as diagnostic biomarkers and therapeutic targets in thyroid cancer and Hashimoto's thyroiditis. 中心基因CLTA、EDIL3、HAPLN1和HIP1作为甲状腺癌和桥本甲状腺炎的诊断生物标志物和治疗靶点的鉴定和功能表征

IF 3.2 4区医学

Clinical and Experimental Medicine Pub Date : 2025-05-15 DOI: 10.1007/s10238-025-01689-w

Tianyu Liu, Dechun Zhang, Wen Ouyang, Rongfang Li, Siying Wang, Weixuan Liu

{"title":"Identification and functional characterization of hub genes CLTA, EDIL3, HAPLN1, and HIP1 as diagnostic biomarkers and therapeutic targets in thyroid cancer and Hashimoto's thyroiditis.","authors":"Tianyu Liu, Dechun Zhang, Wen Ouyang, Rongfang Li, Siying Wang, Weixuan Liu","doi":"10.1007/s10238-025-01689-w","DOIUrl":"10.1007/s10238-025-01689-w","url":null,"abstract":"In this study, we sought to identify key molecular players in both thyroid cancer (TC) and Hashimoto's thyroiditis (HT) by analyzing differentially expressed genes (DEGs) and their potential as biomarkers. We utilized datasets from the Gene Expression Omnibus (GEO) database and identified CLTA, EDIL3, HAPLN1, and HIP1 as hub genes common to both TC and HT. These genes were significantly upregulated in TC cell lines compared to normal controls, with high diagnostic accuracy as indicated by Receiver Operating Characteristic (ROC) curve analysis. Further validation using the TCGA TC dataset revealed their significant upregulation in tumor tissues, particularly in advanced TC stages. Promoter methylation analysis indicated hypomethylation of these genes in TC, suggesting a role of methylation in their regulation. We also observed mutations and copy number variations (CNVs) in these hub genes, with CLTA and HIP1 showing significant amplifications, which may contribute to their overexpression in tumor samples. In addition, we conducted a meta-analysis to assess the impact of these genes on survival outcomes in TC patients, with results indicating that higher expression of HAPLN1 and HIP1 was associated with poor survival. Our study also highlighted the involvement of CLTA and EDIL3 in activating the Rap1 signaling pathway, crucial for cancer cell migration, proliferation, and invasion. These findings emphasize the potential of CLTA, EDIL3, HAPLN1, and HIP1 as diagnostic biomarkers and therapeutic targets for TC and HT.","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"162"},"PeriodicalIF":3.2,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12081531/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Platelet-rich plasma-derived exosomes accelerate the healing of diabetic foot ulcers by promoting macrophage polarization toward the M2 phenotype. 富血小板血浆源性外泌体通过促进巨噬细胞向M2表型极化加速糖尿病足溃疡的愈合。

IF 3.2 4区医学

Clinical and Experimental Medicine Pub Date : 2025-05-15 DOI: 10.1007/s10238-025-01651-w

Ling He, Nan Zhao, Xiaoling Chen, Wenjie Zhang, Kun Lv, Yuanhong Xu

引用次数: 0

Dynamic role of long noncoding RNA in liver diseases: pathogenesis and diagnostic aspects. 长链非编码RNA在肝脏疾病中的动态作用：发病机制和诊断方面。

IF 3.2 4区医学

Clinical and Experimental Medicine Pub Date : 2025-05-14 DOI: 10.1007/s10238-025-01678-z

Ningning Chen, Yunxia Li, Xiaoying Li

{"title":"Dynamic role of long noncoding RNA in liver diseases: pathogenesis and diagnostic aspects.","authors":"Ningning Chen, Yunxia Li, Xiaoying Li","doi":"10.1007/s10238-025-01678-z","DOIUrl":"https://doi.org/10.1007/s10238-025-01678-z","url":null,"abstract":"Liver disease (LD) is complex pathological condition that has emerged as a major threat to human health and the quality of life. Nonetheless, the molecular mechanisms underlying the pathogenesis of LD have not yet been fully elucidated. Recently, a large amount of evidence has shown that long noncoding RNAs (lncRNAs) play important roles in diverse biological processes in the liver. The dysregulation of lncRNAs in the liver, for example, can affect tumor proliferation, migration, and invasion, contribute to hepatic metabolism disorder of lipid and glucose, and shape of hepatic tumoral microenvironment. Thus, a comprehensive understanding of the functional roles of lncRNAs in LD pathogenesis may provide new perspectives for the development of novel diagnostic and therapeutic tools. In the present review, we summarize the current findings on the relationship between lncRNAs and LD, including the modes of action of lncRNAs, the biological significance of lncRNAs in the pathogenesis of LD, especially in hepatocellular carcinoma (HCC) as well as in some non-neoplastic disorders, and the potential use of lncRNAs as diagnostic biomarkers and therapeutic targets for LD.","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"160"},"PeriodicalIF":3.2,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12078412/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A novel composite model for distinguishing benign and malignant pulmonary nodules. 一种区分肺良恶性结节的新型复合模型。

IF 3.2 4区医学

Clinical and Experimental Medicine Pub Date : 2025-05-14 DOI: 10.1007/s10238-025-01672-5

Lei Zhang, Yanhui Xu, Qinqin Lou, Fangfang Chen, Fang Li, Kun Chai, Junshun Gao, Mingjie Tong, Yan Ma, Lilong Xia, Kaixiang Zhao, Junli Gao, Xinhai Zhu

{"title":"A novel composite model for distinguishing benign and malignant pulmonary nodules.","authors":"Lei Zhang, Yanhui Xu, Qinqin Lou, Fangfang Chen, Fang Li, Kun Chai, Junshun Gao, Mingjie Tong, Yan Ma, Lilong Xia, Kaixiang Zhao, Junli Gao, Xinhai Zhu","doi":"10.1007/s10238-025-01672-5","DOIUrl":"10.1007/s10238-025-01672-5","url":null,"abstract":"Previous studies have demonstrated that a four-protein marker panel (4MP), consisting of Pro-SFTPB, CA125, Cyfra21-1, and CEA could be used to identify benign and malignant lung nodules. This study aims to improve the 4MP's performance by combining clinical characteristics and low-dose chest computed tomography (LDCT) screening features. This study involved 380 patients with pulmonary nodules, diagnosing 91 benign and 289 early-stage lung cancer via postoperative histopathology. Serum levels of Pro-SFTPB, CA125, Cyfra21-1, and CEA were assessed using an immunofluorescence assay. Clinical features were selected using the LassoCV method. A new diagnostic model was developed using logistic regression, incorporating 4MP, clinical characteristics, and LDCT features. The model's diagnostic performance was compared to the lung cancer biomarker panel (LCBP) nodule risk model, and evaluated through sensitivity, specificity, and the AUC value. The AUC values for distinguishing between benign and malignant pulmonary nodules were 0.612 for the 4MP model. We screened out 7 factors of patient clinical information and CT features of nodules. The composite model (4MP + age + gender + BMI + family history of cancer + nodule size + nodule margin + nodule density) achieved an AUC of 0.808, especially for small nodules (AUC = 0.835 for nodules ≤ 6 mm). Furthermore, within the same validation cohort, the performance of the composite model (AUC = 0.680) surpassed that of the LCBP nodule risk model (AUC = 0.599). The novel composite model accurately diagnoses malignant pulmonary nodules, especially small ones, helping to stratify patients by lung cancer risk.","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"159"},"PeriodicalIF":3.2,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12078401/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0